A Practical Look at the Clinical Usefulness of the Beta-Lactam/Beta-Lactamase Inhibitor Combinations

Itokazu GS Danziger LH , Ampicillin-sulbactam and ticarcillin–clavulanic acid: A comparison of their in vitro activity and review of their clinical efficacy. Pharmacotherapy 1991; 11:382–414.

Schoonover LL Occhipinti DJ Rodvold KA Danziger LH , Piperacillin/tazobactam: A new beta-lactam/beta-lactamase inhibitor combination. Ann Pharmacother 1995; 29:501–14.

Sanders WE Sanders CC , Piperacillin/tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996; 22:107–23.

Jacoby GA Arcer GL , New mechanisms of bacteria resistance to antimicrobial agents. N Engl J Med 1991; 324:601–12.

Medeiros AA , β-Lactamases. Br Med Bull 1984; 40:18–27.

Mayer KH Opal SM Medeiros AA , Mechansims of antibiotic resistance. In: Mandell GL Douglas RG Bennett JE , eds. Principles and practice of infectious diseases. New York: Churchill Livingston, 1995:212–25.

Akova M Yang Y Livermore DM , Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed class I β-lactamases. J Antimicrob Chemother 1990; 25:199–208.

Labia R Morand A Lelievre V Mattioni D Kazmierczak A. Sulbactam: Biochemical factors involved in its synergy with ampicillin. Rev Infect Dis 1986; 8(suppl 5):496–502.

Reading C Farmer T. The inhibition of β-lactamases from gram-negative bacteria by clavulanic acid. Biochem J 1981; 199:779–87.

Arisawa M Then RL , 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent β-lactamase inhibitor. I. Inhibition of chromosomally and R-factor-mediated β-lactamases. J Antibiot 1982; 35:1578–83.

Fass RJ Prior RB , Comparative in vitro activities of piperacillin–tazobactam and ticarcillin–clavulanate. Antimicrob Agents Chemother 1989; 33:1268–74.

Richmond MH Sykes RB , The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973; 9:31–88.

Sykes RB Matthew M. The β-lactamases of gram-negative bacteria and their role in resistance in β-lactam antibiotics. J Antimicrob Chemother 1976; 2:115–57.

Ambler RP , The structure of β-lactamases. Philos Trans R Soc Lond B 1980; 289:321–31.

Fu KP Neu HC , Comparative inhibition of β-lactamases by novel β-lactam compounds. Antimicrob Agents Chemother 1979; 15:171–6.

Bauernfeind A. Classification of β-lactamases. Rev Infect Dis 1986; 8(suppl 5):470–81.

Neu HC Fu KP , Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrob Agents Chemother 1978; 14:650–5.

Weber DA Sanders CC , Diverse potential of β-lactamase inhibitors to induce class I enzymes. Antimicrob Agents Chemother 1990; 34:156–8.

Livermore DM Akora M Wu P Yang Y. Clavulanate and β-lactamase induction. J Antimicrob Chemother 1989; 24(suppl B):23–33.

Yourassowsky E Van der Linden MP Lismont MJ Crokaert F. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination. Chemotherapy 1990; 36:215–21.

Coleman K Griffin DRJ Page JWJ Upshon PA , In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 1989; 33:1580–7.

Thornsberry C. Trends in antimicrobial resistance among today's bacterial pathogens. Pharmacotherapy 1995; 15 (1 pt 2):35–85.

Scully BE Chin N-X Neu HC , Pharmacology of ticarcillin combined with clavulanic acid in humans. Am J Med 1985; 79(suppl 5B):39–43.

Meyers BR Wilkinson P Mendelson MH Walsh S Bournazos C Hirschman SZ , Pharmocokinetics of ampicillin–sulbactam in healthy elderly and young volunteers. Antimicrob Agents Chemother 1991; 35:2098–101.

Wise R Logan M Cooper M Andrews JM , Pharmocokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991; 35:1081–4.

Dalet F Amado E Cabrera E Donate T del Rio G . Pharmacokinetics of the combination of ticarcillin with clavulanic acid in renal insufficiency. J Antimicrob Chemother 1986; 17(suppl C):57–64.

Hardin TC Butler SC Ross S Wakeford JH Jorgensen JH , Comparison of ampicillin-sulbactam and ticarcillin–clavulanic acid in patients with chronic renal failure: Effects of differential pharmacokinetics on serum bactericidal activity. Pharmacotherapy 1994; 14:147–52.

Johnson CA Halstenson CE Kelloway JS Shapiro BE Zimmerman SW Tonelli A , Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992; 51:32–41.

Blum RA Kohli RK Harrison NJ Schentag JJ , Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989; 33:1470–6.

Package information. Unasyn (ampicillin/sulbactam). New York: Pfizer Roerig, Division of Pfizer Inc., January 1994.

Package information. Timentin (ticarcillin/clavulanate). Bristol, TN: Beecham Laboratories, Division of Beecham Inc., September 1988.

Package information. Zosyn (piperacillin/tazobactam). Pearl River, NY: Lederle Laboratories, October 1993.

Bergan T Olszewski W Engeset A. Penetration to peripheral lymph of clavulanic acid and ticarcillin. J Antimicrob Chemother 1986; 17:97–103.

Adam D Heilmann HD Weismeier K. Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of Timentin. Antimicrob Agents Chemother 1987; 31:935–9.

Meier H Adam D Heilmann HD , Penetration of ticarcillin/clavulanate into cartilage. J Antimicrob Chemother 1989; 24(suppl B): 101–5.

Parry MF Neu HC , Ticarcillin for treatment of serious infections with gram-negative bacteria. J Infect Dis 1976; 134:476–85.

Franz P von Rosen F Garner C Swozil U Schmiedek P Einhäupl K , Cerebrospinal fluid penetration after single or multiple dosage with ticarcillin/clavulanate. J Antimicrob Chemother 1989; 24(suppl B):107–10.

Blackwell BG Leggett JE Johnson CA Zimmerman SW Craig WA , Ampicillin and sulbactam pharmacokinetics in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:221–6.

Wildfeuer A Müller V Springsklee M Sonntag HG , Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery. Antimicrob Agents Chemother 1991; 35:1772–6.

Houang ET Colley N Chapman M. Penetration of sulbactam–ampicillin and clavulanic acid-amoxicillin into pelvic peritoneum. Antimicrob Agents Chemother 1985; 28:165–6.

Morris DL Ubhi CS Robertson CS Brammer KW , Biliary pharmacokinetics of sulbactam plus ampicillin in humans. Rev Infect Dis 1986; 8(suppl 5):589–92.

Frank U Schmidt-Eisenlohr E Joos-Württemberger A Hasse J Daschner F. Concentrations of sulbactam/ampicillin in serum and lung tissue. Infection 1990; 18:307–9.

Stahl JP Bru JP Fredj G Brammer KW Malleret MR Micoud M. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis 1986; 8(suppl 5):612–6.

Hänninen P Rossi T. Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis. Rev Infect Dis 1986; 8(suppl 5):609–11.

Kinzig M Sörgel F Brismar B Nord CE , Pharmacokinetics and tissue penetration of ticarcillin and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1992; 36:1997–2004.

Kinzig M Sörgel F Naber KG Kujath P Nord CE Brismar B , Tissue penetration of piperacillin/tazobactam (abstract). Proceedings of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991.

Jehl F Muller-Serieys C De Larminat V Monteil H Bergogne-Berezin E. Penetration of piperacillin–tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 1994; 38:2780–4.

Piperacillin/tazobactam. Med Lett 1994; 36 (January 21):7–9.

Schlech WF III Ward JI Band JD Hightower A Fraser DW Broome CV , Bacterial meningitis in the United States, 1978 through 1981. The national bacterial meningitis surveillance study. JAMA 1985: 253:1749–54.

Wenger JD Hightower AW Facklam RR Gaventa S , Broome CV, the Bacterial Meningitis Study Group. Bacterial meningitis in the United States, 1986: Report of a multistate surveillance study. J Infect Dis 1990; 162:1316–23.

Dutse AI Fakunle YM Oyeyinka GO Bello CSS , Sulbactam/ampicillin in the treatment of epidemic meningococcal meningitis in Northern Nigeria. Drugs 1988; 3(suppl 7):77–9.

Butler JC Breiman RF Facklam RR , Pneumococcal Working Group. Emergence of drug-resistant pneumococci in the United States (abstract). Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993.

Pankuch GA Jacobs MR Appelbaum PC , Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin–tazobactam, ticarcillin, ticarcillin–clavulanate, ampicillin, ampicillin–sulbactam, ceftazidime, and ceftriaxone. Antimicrob Agents Chemother 1994; 38:2905–7.

Friedland IR McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377–82.

Tablan OC Anderson LJ Arden NH Breiman RF Butler JC McNeil MM , Guideline for prevention of nosocomial pneumonia. Part I. Issues on prevention of nosocomial pneumonia — 1994. Am J Infect Control 1994; 22:247–92.

Peacock JE Jr Sorrell L Sottile FD Price LE , Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Actnetobacter calcoaceticus var. anitratus: Epidemiologic characteristics and clinical significance. Infect Control Hosp Epidemiol 1988; 9:302–8.

Go ES Urban C Burns J Kreiswirth B Eisner W Mariano N , Clinical and molecular epidemiology of Acinetobacler infections sensitive only to polymixin B and sulbactam. Lancet 1994; 34:1329–32.

Fink MP Snydman DR Niederman MS Leeper KV Jr Johnson RH Heard SO , Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. Antimicrob Agents Chemother 1994; 38:547–57.

Job ML Dretler RH , Seizure activity with imipenem therapy: Incidence and risk factors. DICP Ann Pharmacother 1990; 24:467–9.

Calandra G Lydick E Carrigan J Weiss L Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med 1988; 84:911–8.

Leo RJ Ballow CH , Seizure activity associated with imipenem use: Clinical case reports and review of the literature. DICP Ann Pharmacother 1991; 25:351–4.

Schwigon CD Hulla FW Schulze B Maslak A. Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units. J Antimicrob Chemother 1986; 17(suppl C):115–22.

Brittain DC Scully BE Neu HC , Ticarcillin plus clavulanic acid in the treatment of pneumonia and other serious infections. Am J Med 1985; 79(suppl 5B):81–3.

Inthorn D Mühlbayer D Hartl WH , Ticarcillin/clavulanate in the treatment of severe peritonitis. J Antimicrob Chemother 1989; 24(suppl B):141–6.

Fink MP Helsmoortel CM Arous EJ Doern GV Moriarty KP Fairchild PG , Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra-abdominal infections. J Antimicrob Chemother 1989; 24(suppl B):147–56.

Study Group of Intraabdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: A preliminary report. Rev Infect Dis 1986; 8(suppl 5):583–8.

Brismar B Malmborg AS Tunevall G Wretlind B Bergman L Mentzing LO , Piperacillin–tazobactam versus imipenem–cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36:2766–73.

Niinikoski J Havia T Alhava E Pääkkönen M Miettinen P Kivilaakso E , Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176:255–61.

Drusano GL , Pharmacology of anti-infective agents. In: Mandell GL Douglas RG Bennett JE , eds. Principles and practice of infectious diseases. New York: Churchill Livingston, 1995:225–32.

Tan JS Wishnow RM Talan DA Duncanson FP , Norden CW, the Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin–tazobactam versus ticarcillin–clavulanate. Antimicrob Agents Chemother 1993; 37:1580–6.

Loffler L Bauernfeind A Keyl W Hoffstedt B Piergie SA Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Rev Infect Dis 1986; 8(suppl 5):593–8.

Stromberg BV Reines HD Junt P. Comparative clinical study of sulbactam and ampicillin and clindamycin and tobramycin in infections of soft tissues. Surg Gynecol Obstet 1986; 162:575–8.

File TM Jr Tan JS . Ticarcillin–clavulanate therapy for bacterial skin and soft tissue infections. Rev Infect Dis 1991; 13(suppl 9):733–6.

Jones RN Pfaller MA Fuchs PC Aldridge K Allen SD Gerlach EH , Piperacillin/tazobactam (YTR 830) combination: Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis 1989; 12:489–94.

O'Keefe JP Venezio FR Divincenzo CA Shatzer KL , Activity of newer β-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother 1987; 31:2002–4.

Retsema JA English AR Girard A Lynch JE Anderson M Brennan L , Sulbactam/ampicillin: In vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 1986; 8(suppl 5):528–34.

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S5, National Committee for Clinical Laboratory Standards, Informational Supplement, December 1994.

Moellering RC Jr. Principles of anti-infective therapy. In: Mandell GL Douglas RG Bennett JE , eds. Principles and practice of infectious diseases. New York: Churchill Livingston, 1995:199–212.

1995 Red book. Boulder, CO: Medical Economics Data Inc., 1995.